Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment.

Brooke R Druliner Krishna R Kalari Sisi Qin Scott M Dehm Vipul Bhargava Michael Gormley Winston Tan Jason P Sinnwell David W Hillman Ying Li Peter T Vedell Rachel E Carlson Alan H Bryce Raphael E Jimenez Richard M Weinshilboum Manish Kohli Liewei Wang

Published in: Molecular cancer research : MCR (2022)

Finally, we identified candidates drugs to reverse AA/P resistance: topoisomerase inhibitors and drugs targeting the cell cycle via the MYC/AURKA/AURKB/TOP2A and/or PI3K_AKT_MTOR pathways.

Keyphrases

cell cycle
prostate cancer
cell proliferation
radical prostatectomy
cancer therapy
transcription factor
drug delivery
drug induced